Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magali Olivier

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Current Opinion in Oncology|November 4, 2010
Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genesMagali Olivier, Philippe Taniere
Cold Spring Harbor Perspectives in Biology|February 26, 2010
TP53 mutations in human cancers: origins, consequences, and clinical useMagali Olivier, Monica Hollstein, Pierre Hainaut
International Journal of Cancer|June 16, 2010
p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell linesLynnette Fernandez-Cuesta, Suresh Anaganti, Pierre Hainaut, et al.
Breast Cancer Research and Treatment|March 12, 2010
Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell linesLynnette Fernández-Cuesta, Suresh Anaganti, Pierre Hainaut, et al.
Cancer|August 13, 2011
Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 databaseSimona Ognjanovic, Magali Olivier, Tracy L Bergemann, et al.
Cancer Letters|November 13, 2010
p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-linesSuresh Anaganti, Lynnette Fernández-Cuesta, Anita Langerød, et al.
Critical Reviews in Clinical Laboratory Sciences|December 18, 2004
The tumor suppressor gene TP53: implications for cancer management and therapySeverine Seemann, Daniela Maurici, Magali Olivier, et al.
Nature Reviews. Cancer|September 25, 2012
Upper urinary tract urothelial cancers: where it is A:TMagali Olivier, Monica Hollstein, Heinz Hans Schmeiser, et al.
Human Mutation|January 6, 2006
Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellationsEwy Mathe, Magali Olivier, Shunsuke Kato, et al.
Sarcoma|May 3, 2012
Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric RhabdomyosarcomaSimona Ognjanovic, Ghyslaine Martel, Carlos Manivel, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Current Opinion in Oncology|November 4, 2010
Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genesMagali Olivier, Philippe Taniere
Cold Spring Harbor Perspectives in Biology|February 26, 2010
TP53 mutations in human cancers: origins, consequences, and clinical useMagali Olivier, Monica Hollstein, Pierre Hainaut
International Journal of Cancer|June 16, 2010
p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell linesLynnette Fernandez-Cuesta, Suresh Anaganti, Pierre Hainaut, et al.
Breast Cancer Research and Treatment|March 12, 2010
Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell linesLynnette Fernández-Cuesta, Suresh Anaganti, Pierre Hainaut, et al.
Cancer|August 13, 2011
Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 databaseSimona Ognjanovic, Magali Olivier, Tracy L Bergemann, et al.
Cancer Letters|November 13, 2010
p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-linesSuresh Anaganti, Lynnette Fernández-Cuesta, Anita Langerød, et al.
Critical Reviews in Clinical Laboratory Sciences|December 18, 2004
The tumor suppressor gene TP53: implications for cancer management and therapySeverine Seemann, Daniela Maurici, Magali Olivier, et al.
Nature Reviews. Cancer|September 25, 2012
Upper urinary tract urothelial cancers: where it is A:TMagali Olivier, Monica Hollstein, Heinz Hans Schmeiser, et al.
Human Mutation|January 6, 2006
Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellationsEwy Mathe, Magali Olivier, Shunsuke Kato, et al.
Sarcoma|May 3, 2012
Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric RhabdomyosarcomaSimona Ognjanovic, Ghyslaine Martel, Carlos Manivel, et al.
Pageof 6